Communiqués Sorrento Therapeutics, Inc.

Actions

SRNE

US83587F2020

Recherche biotechnologique et médicale

Cours en clôture OTC Markets 28/08/2026			Varia. 5j.	Varia. 1 janv.
0,000500 ^USD	0,00%		-37,50%	-80,77%

17/03	Semnur Pharmaceuticals, Inc. annonce un changement de direction générale, effectif au 13 mars 2026	CI
17/03	Semnur Pharmaceuticals, Inc. annonce des changements au sein de sa direction	CI

Communiqués

26/09/24	Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025	AQ
10/05/24	Ninth Circuit Rules That Biopharmaceutical Company's Announcement Of COVID-19 "Cure" Did Not Violate Securities Laws	AQ
15/04/24	Ninth Circuit Affirms Dismissal Of Putative Securities Class Action Against Biopharmaceutical Company Over Statements It Had Developed A COVID "Cure"	AQ
22/09/23	Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company	PR
13/09/23	Sorrento Therapeutics : NON-BINDING TERM SHEET - Form 8-K	PU
12/09/23	Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19	AQ
07/09/23	Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients	AQ
27/07/23	Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders	AQ
21/07/23	/C O R R E C T I O N -- Sorrento Therapeutics, Inc./	PR
20/07/23	Sorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders	PR
15/06/23	Sorrento Therapeutics, Inc.'s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock	PR
14/05/23	Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts	PR
26/04/23	Sorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend	PR
20/04/23	SORRENTO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/04/23	SORRENTO THERAPEUTICS, INC. Other Events, Financial Statements and Exhibits (form 8-K/A)	AQ
10/04/23	SORRENTO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/04/23	Sorrento Therapeutics, Inc.'s Bankruptcy Court Requires Brokerages to Provide Information Related to Scilex Common Stock	PR
31/03/23	SORRENTO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
29/03/23	Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Possession Financing	PR
20/03/23	SORRENTO THERAPEUTICS, INC. : Other Events, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
17/03/23	Court Confirms Sorrento Therapeutics, Inc.'s $125 Million Arbitration Award Against NantPharma, LLC	PR
16/03/23	SORRENTO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
22/02/23	SORRENTO THERAPEUTICS, INC. : Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
21/02/23	Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case	PR
21/02/23	SORRENTO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ